FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550659816> ?p ?o ?g. }

• W2550659816 abstract "<h3>Background</h3> In rheumatology, comorbid infections have significant impact on patients’ morbidity, mortality and quality of life. Prevention of infections is an integral part of supervision of these patients. <h3>Objectives</h3> The aim of the study is to investigate immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with rheumatoid arthritis (RA) in a five-years period. <h3>Methods</h3> The study included 79 RA patients with ≥2 recent episodes of respiratory tract infections (bronchitis, pneumonia). 52 RA pts were treated with methotrexate (MT), 14 – with leflunomide (Lef), 13– with TNF- α inhibitors + MT. One dose (0,5 ml) of PPV-23 was administered subcutaneously without discontinuing MT/Lef or 28-30 days prior to initiation of TNF- α inhibitors. Control visits were scheduled as follows: at baseline (Visit 1), and in 1, 3, and every year after immunization. 39 out of 110 pts were followed for 24 months, 23 pts – for 36 months, 23 pts – for 48 months, and 18 - for 60 months. Standard clinical examination and lab tests were performed at each visit. Levels of serum antibodies (AB) to Pneumococcal capsular polysaccharide were measured with VaccZymeTM PCP IgG 2 panels (The Binding Site Group Ltd, Birmingham, UK). Coefficient of post-immunization response (CPR) was determined for each patient as the ratio of AB levels at Visits II, III, IV, V, VI and VII to AB level at Visit I. <h3>Results</h3> 53 (67%) patients did not have any reactions to the vaccine, 26 (33%) patients indicated pain, swelling and hyperemia of the skin (diameter up to 2 cm) at the injection site of the vaccine, low-grade fever. These typical reactions following vaccination are completely regressed within days without any additional treatment. They were not associated with RA therapy and did not require changes in ist schemes. Pronounced positive immune reaction to PPV-23 was documented in all RA patients on different therapeutic regimens as significant AB incremental growth. Significantly high level of post-immunization response still persisted after 4 and 5 years of follow-up.The proportion of responders to PPV-23 after 5 years reached 73% among RA patients. (Table). No case of clinically or radiographically confirmed pneumonia was documented during the follow up period, although one case of interstitial viral pneumonia was registered in 6 month after immunization. Not a single vaccination-related RA exacerbation episode or new autoimmune phenomenon was documented during the follow-up. *p<0,05 <h3>Conclusion</h3> Thus, all given prove the sufficient immunogenicity and safety of 23-valent pneumococcal vaccine in RA patients after 5 years of follow-up, getting different therapeutic regimens. <h3>Disclosure of Interests</h3> None declared" @default.
• W2550659816 created "2016-11-30" @default.
• W2550659816 creator A5001344521 @default.
• W2550659816 creator A5009658580 @default.
• W2550659816 creator A5011150630 @default.
• W2550659816 creator A5025976331 @default.
• W2550659816 creator A5037294287 @default.
• W2550659816 creator A5049547284 @default.
• W2550659816 creator A5073493598 @default.
• W2550659816 creator A5080159247 @default.
• W2550659816 date "2019-06-01" @default.
• W2550659816 modified "2023-09-26" @default.
• W2550659816 title "THU0127 IMMUNOGENICITY AND SAFETY OF 23-VALENT PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM 5-YEAR FOLLOW UP" @default.
• W2550659816 doi "https://doi.org/10.1136/annrheumdis-2019-eular.3173" @default.
• W2550659816 hasPublicationYear "2019" @default.
• W2550659816 type Work @default.
• W2550659816 sameAs 2550659816 @default.
• W2550659816 citedByCount "5" @default.
• W2550659816 countsByYear W25506598162019 @default.
• W2550659816 countsByYear W25506598162020 @default.
• W2550659816 countsByYear W25506598162021 @default.
• W2550659816 countsByYear W25506598162023 @default.
• W2550659816 crossrefType "proceedings-article" @default.
• W2550659816 hasAuthorship W2550659816A5001344521 @default.
• W2550659816 hasAuthorship W2550659816A5009658580 @default.
• W2550659816 hasAuthorship W2550659816A5011150630 @default.
• W2550659816 hasAuthorship W2550659816A5025976331 @default.
• W2550659816 hasAuthorship W2550659816A5037294287 @default.
• W2550659816 hasAuthorship W2550659816A5049547284 @default.
• W2550659816 hasAuthorship W2550659816A5073493598 @default.
• W2550659816 hasAuthorship W2550659816A5080159247 @default.
• W2550659816 hasBestOaLocation W25506598161 @default.
• W2550659816 hasConcept C126322002 @default.
• W2550659816 hasConcept C159654299 @default.
• W2550659816 hasConcept C197934379 @default.
• W2550659816 hasConcept C198451711 @default.
• W2550659816 hasConcept C203014093 @default.
• W2550659816 hasConcept C2775905006 @default.
• W2550659816 hasConcept C2777575956 @default.
• W2550659816 hasConcept C2779301066 @default.
• W2550659816 hasConcept C2779664119 @default.
• W2550659816 hasConcept C2780868878 @default.
• W2550659816 hasConcept C2781059491 @default.
• W2550659816 hasConcept C2781253189 @default.
• W2550659816 hasConcept C3020803494 @default.
• W2550659816 hasConcept C501593827 @default.
• W2550659816 hasConcept C71924100 @default.
• W2550659816 hasConcept C86803240 @default.
• W2550659816 hasConcept C89423630 @default.
• W2550659816 hasConcept C90924648 @default.
• W2550659816 hasConceptScore W2550659816C126322002 @default.
• W2550659816 hasConceptScore W2550659816C159654299 @default.
• W2550659816 hasConceptScore W2550659816C197934379 @default.
• W2550659816 hasConceptScore W2550659816C198451711 @default.
• W2550659816 hasConceptScore W2550659816C203014093 @default.
• W2550659816 hasConceptScore W2550659816C2775905006 @default.
• W2550659816 hasConceptScore W2550659816C2777575956 @default.
• W2550659816 hasConceptScore W2550659816C2779301066 @default.
• W2550659816 hasConceptScore W2550659816C2779664119 @default.
• W2550659816 hasConceptScore W2550659816C2780868878 @default.
• W2550659816 hasConceptScore W2550659816C2781059491 @default.
• W2550659816 hasConceptScore W2550659816C2781253189 @default.
• W2550659816 hasConceptScore W2550659816C3020803494 @default.
• W2550659816 hasConceptScore W2550659816C501593827 @default.
• W2550659816 hasConceptScore W2550659816C71924100 @default.
• W2550659816 hasConceptScore W2550659816C86803240 @default.
• W2550659816 hasConceptScore W2550659816C89423630 @default.
• W2550659816 hasConceptScore W2550659816C90924648 @default.
• W2550659816 hasLocation W25506598161 @default.
• W2550659816 hasOpenAccess W2550659816 @default.
• W2550659816 hasPrimaryLocation W25506598161 @default.
• W2550659816 hasRelatedWork W1971595431 @default.
• W2550659816 hasRelatedWork W2026870379 @default.
• W2550659816 hasRelatedWork W2044163764 @default.
• W2550659816 hasRelatedWork W2046005537 @default.
• W2550659816 hasRelatedWork W2082015588 @default.
• W2550659816 hasRelatedWork W2127989327 @default.
• W2550659816 hasRelatedWork W2155580802 @default.
• W2550659816 hasRelatedWork W2372955595 @default.
• W2550659816 hasRelatedWork W2394123269 @default.
• W2550659816 hasRelatedWork W4206788802 @default.
• W2550659816 isParatext "false" @default.
• W2550659816 isRetracted "false" @default.
• W2550659816 magId "2550659816" @default.
• W2550659816 workType "article" @default.